Morphinsulfat Pro Al (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Morphinsulfat Pro Al, is an opioid analgesic presented as an oral formulation for systemic use. It is employed to manage moderate to severe pain in adult patients when non‑opioid therapies are insufficient. The drug acts centrally on the nervous system to provide analgesia and sedation, and is classified as a Schedule II controlled substance in the EU.

GNH USA supplies Morphinsulfat Pro Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine Sulfate is an opioid analgesic used in the management of pain across several clinical contexts.

- Acute postoperative pain: provides rapid analgesia to facilitate recovery after surgery. - Cancer‑related pain: offers sustained relief for malignant disease‑associated discomfort. - Severe chronic non‑cancer pain: reduces persistent pain when other treatments are inadequate.

Common side effects are typically mild to moderate and may affect many patients during therapy.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: upset stomach often occurring early in treatment. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness. - Dry mouth: decreased salivation. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Addiction or dependence: risk of misuse with prolonged use. - Adrenal insufficiency: impaired cortisol response. - Anaphylaxis: rare severe allergic reaction. - Seizures: uncommon but reported in isolated cases.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse outcomes. - Assess pain severity: confirm that opioid therapy is appropriate for the level of pain. - Evaluate respiratory function: ensure adequate baseline ventilation. - Monitor for signs of dependence: watch for escalating dose requirements. - Adjust dose in renal or hepatic impairment: consider reduced clearance. - Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Morphine Sulfate can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise morphine plasma levels. - Respiratory depressants (e.g., gabapentinoids at high doses): enhance sedation. - Other opioids: additive opioid effect leading to overdose.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: can potentiate hypotensive effects. - Antihistamines: may increase drowsiness. - Alcohol: can augment central nervous system depression. - Serotonergic agents (e.g., SSRIs): monitor for serotonin syndrome signs.